FLT3 and acute myeloid leukemia: The direct targeting of this kinase with a recently developed inhibitor quizartinib, for instance, has been shown to impair growth of FLT3-ITD-positive leukemia in vitro and in murine models and has induced dramatic responses in patients with AML [1].